| 12/11/2012 | CV | Medicis amends conversion right for 1.5%, 2.5% and 1.375% notes
|
| 9/5/2012 | CV | Market Commentary: Toll Brothers trades unchanged on debut; Medicis in another 0.125 point; IG names active
|
| 9/4/2012 | CV | Market Commentary: Planned Toll Brothers deal gets tepid reaction; Medicis mixed; Knight Capital edges up
|
| 9/4/2012 | CVLM | Medicis to repurchase convertibles with funds from Valeant debt issue
|
| 8/9/2012 | CV | Market Commentary: New Exelixis gains on debut; new Prospect Capital prices at a discount; Medicis better
|
| 5/16/2012 | CV | Medicis greenshoe exercised, ups 1.375% convertibles $500 million
|
| 5/11/2012 | CV | New Issue: Medicis prices upsized $450 million five-year convertibles to yield 1.375%, up 25%
|
| 5/11/2012 | CV | Market Commentary: New Medicis, Ryland upsized, trade flat to up slightly in secondary; Chesapeake pressured
|
| 5/10/2012 | CV | Medicis plans $400 million five-year convertible notes to yield 1.5%-2%, up 20%-25%
|
| 5/10/2012 | CV | Medicis revises talk on $400 million five-year convertible notes to 1%-1.5%, up 25%
|
| 5/10/2012 | CV | Market Commentary: Planned Medicis convertible adds in gray despite revised terms; planned Ryland seen cheap
|
| 5/10/2012 | CVIGPF | Medicis files automatic shelf registration for stock, preferreds, debt
|
| 8/11/2008 | CV | Medicis to buy back remaining 1.5% convertibles
|
| 6/6/2008 | CV | Medicis gets puts for $283.7 million of 1.5% convertibles
|
| 1/31/2008 | CV | Market Commentary: Digital Realty lowers talk; Cadence Design hammered on outlook; Cameron down; BofA, WaMu 'rip'
|
| 7/12/2007 | CV | Medicis gets puts for $5,000 of 2.5% convertibles
|
| 11/9/2006 | BT | RBC keeps Medicis at outperform
|
| 11/8/2006 | BT | RBC keeps Medicis at outperform, ups target
|
| 10/9/2006 | BT | Medicis reaching for broader market of 23 million women for Restylane products
|
| 10/2/2006 | BT | RBC reiterates Medicis at outperform
|
| 9/26/2006 | BT | Medicis reiterated at outperform
|
| 9/25/2006 | BT | RBC maintains Medicis at outperform
|
| 9/11/2006 | BT | Medicis kept at outperform by RBC
|
| 9/8/2006 | BT | Medicis expects FDA approval of Perlane, undisclosed drug in Q4
|
| 9/5/2006 | BT | RBC keeps Medicis at outperform
|
| 8/28/2006 | BT | Medicis kept at outperform by RBC
|
| 8/21/2006 | BT | RBC reiterates Medicis at outperform
|
| 8/16/2006 | BT | RBC reiterates Medicis at outperform
|
| 8/14/2006 | BT | RBC reiterates Medicis at outperform
|
| 8/7/2006 | BT | Medicis reiterated at outperform by RBC
|
| 8/3/2006 | BT | Medicis reiterated at outperform by RBC
|
| 8/1/2006 | BT | RBC reiterates Medicis at outperform
|
| 7/12/2006 | BT | Ipsen: No deal with Medicis for botulinum toxin product due to lack of European distribution network
|
| 6/19/2006 | BT | Medicis hopes to gain approval for another pipeline product this year
|
| 5/8/2006 | BT | FDA approves Medicis' minocycline HCl, USP Extended Release Tablets for acne
|
| 4/12/2006 | BT | Medicis receives two patents for Loprox gel
|
| 3/2/2006 | BT | Medicis announces FDA OK of broader indication for Vanos cream
|
| 12/13/2005 | BT | Medicis, Inamed terminate merger deal; Inamed pays $90 million fee, clearing way for Allergan offer
|
| 12/13/2005 | BT | Market Commentary: CuraGen sinks; Indevus soars; Voyager pulls IPO; Insmed up on FDA approval; Tercica falls
|
| 12/6/2005 | BT | Inamed's board says Allergan's $3.2 billion merger offer tops Medicis offer, but remains neutral
|
| 11/22/2005 | BT | Medicis wants Inamed to recommend that stockholders reject Allergan's rival merger offer
|
| 11/21/2005 | BT | Medicis rebuffs Mentor's $2.2 billion merger offer, says it is committed to deal with Inamed
|
| 11/21/2005 | BT | Market Commentary: Incyte zooms on R&D pact with Pfizer; Medicis, Mentor, Allergan, Inamed tangle in merger scuffle
|
| 11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
| 11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
| 11/15/2005 | BT | Allergan unveils $3.2 billion bid for Inamed, topping Medicis offer by $450 million
|
| 6/30/2005 | BT | Market Commentary: Elan shares move up, credit lags, Connetics rises against the tide; Medicis, Inamed up; Millipore off
|
| 6/30/2005 | CV | Market Commentary: Saks, Kodak and General Mills trade in a mixed convertibles market; June marks improvements
|
| 6/30/2005 | BT | Medicis initiated by Leerink Swann at outperform
|
| 6/3/2005 | BK | Market Commentary: Berry Plastics C loan breaks in mid-101 context; General Growth falls to par as repricing resurfaces
|
| 4/1/2004 | CV | Market Commentary: Massey at 101.25 in gray market; UnitedGlobalCom's euro convert trades down to 99; retailers routed
|
| 8/20/2003 | CV | Market Commentary: Full-blown summer session very quiet, but a few buyers emerge for cheaper issues
|
| 8/14/2003 | CV | Medicis announced $230 million of convertibles tendered for exchange
|
| 8/12/2003 | CV | Market Commentary: Reliant converts plunge 16.25 points as broader market gains; Cadence deal reoffered at 98
|
| 7/18/2003 | CV | Market Commentary: Interrnet issues rocket higher; overall market rebounds slightly; call threats keep a lid on gains
|
| 7/16/2003 | CV | Medicis starts exchange offer for 2.5% convertibles to take advantage of strong market
|
| 4/3/2003 | CV | Market Commentary: Refinancing hopes, quest for delta provide buying catalyst; HealthSouth firmer on rescue hopes
|
| 5/30/2002 | CV | New Issue: Medicis $350 million convertibles at 2.5% yield, up 25%
|
| 5/30/2002 | CV | Medicis seen clearing way for more CoCo converts; TXU could usher in more energy mandatories
|
| 5/30/2002 | CV | Market Commentary: Adelphia, El Paso slip further on worries but market, new issues mostly higher
|
| 5/29/2002 | CV | Market Commentary: El Paso's dive takes energy, power lower; Mentor, Medicis, TXU higher in gray market
|
| 5/28/2002 | CV | Medicis $350 million convertibles talked at 2.5-3.0% yield, up 20-25%
|
| 5/28/2002 | CV | Market Commentary: Primary gets shot in arm with four new deals; secondary sluggish as many eye Adelphia 8-K
|
